HLA DR4 IS A MARKER FOR RAPID DISEASE PROGRESSION IN PRIMARY SCLEROSING CHOLANGITIS

被引:88
作者
MEHAL, WZ
LO, YMD
WORDSWORTH, BP
NEUBERGER, JM
HUBSCHER, SC
FLEMING, KA
CHAPMAN, RW
机构
[1] JOHN RADCLIFFE HOSP,DEPT GASTROENTEROL,OXFORD OX3 9DU,OXON,ENGLAND
[2] JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD,OXON,ENGLAND
[3] JOHN RADCLIFFE HOSP,MED CLIN,OXFORD,OXON,ENGLAND
[4] QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND
[5] UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM,W MIDLANDS,ENGLAND
[6] JOHN RADCLIFFE HOSP,DEPT GASTROENTEROL,OXFORD,OXON,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1016/S0016-5085(94)95085-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Primary sclerosing cholangitis (PSC) is an inflammatory disease of the biliary tree associated with an increase in the HLA alleles DR3, DR52a, DR2, Dw2, and a decrease in DR4. However, it is not certain which of these alleles provides the primary associations. Our aim was to establish the primary HLA associations with PSC and to assess the ability of HLA alleles to mark for disease progression. Methods: By applying molecular techniques to archival tissue, we have genotyped 83 PSC patients from two populations and 131 controls for the alleles HLA DR2, DR3, DR4, DRw12, DR52a, and Dw2. Results: HLA DR3, DR52a, DR2, and Dw2 were all significantly increased in PSC, with the relative risk for DR52a and Dw2 being greater than for DR3 and DR2, respectively. HLA DR4 was significantly decreased, but this may be artifactual to the DR3, DR2 increase. HLA DR4 and not DR52a marks for rapid disease progression in both our PSC populations. Conclusions: HLA DR52a and Dw2 are the best candidate alleles for providing the known HLA association with PSC. HLA DR4 and not DR52a marks for rapid disease progression in our two PSC populations. © 1994 American Gastroenterological Association.
引用
收藏
页码:160 / 167
页数:8
相关论文
共 32 条
  • [1] ARMITAGE P, 1987, STATISTICAL METHODS
  • [2] ANALYSIS OF HLA-DQ GENOTYPES AND SUSCEPTIBILITY IN INSULIN-DEPENDENT DIABETES-MELLITUS
    BAISCH, JM
    WEEKS, T
    GILES, R
    HOOVER, M
    STASTNY, P
    CAPRA, JD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (26) : 1836 - 1841
  • [3] MEASURING THE STRENGTH OF ASSOCIATIONS BETWEEN HLA ANTIGENS AND DISEASES
    BENGTSSON, BO
    THOMSON, G
    [J]. TISSUE ANTIGENS, 1981, 18 (05): : 356 - 363
  • [4] ASSOCIATION OF PRIMARY SCLEROSING CHOLANGITIS WITH HLA-B8
    CHAPMAN, RW
    VARGHESE, Z
    GAUL, R
    PATEL, G
    KOKINON, N
    SHERLOCK, S
    [J]. GUT, 1983, 24 (01) : 38 - 41
  • [5] CHAPMAN RW, 1990, SPRINGER SEMIN IMMUN, V12, P121
  • [6] CHAPMAN RW, 1982, GUT, V22, pA871
  • [7] PRIMARY SCLEROSING CHOLANGITIS - A REVIEW OF ITS CLINICAL-FEATURES, CHOLANGIOGRAPHY, AND HEPATIC HISTOLOGY
    CHAPMAN, RWG
    ARBORGH, BAM
    RHODES, JM
    SUMMERFIELD, JA
    DICK, R
    SCHEUER, PJ
    SHERLOCK, S
    [J]. GUT, 1980, 21 (10) : 870 - 877
  • [8] PRIMARY SCLEROSING CHOLANGITIS - REFINEMENT AND VALIDATION OF SURVIVAL MODELS
    DICKSON, ER
    MURTAUGH, PA
    WIESNER, RH
    GRAMBSCH, PM
    FLEMING, TR
    LUDWIG, J
    LARUSSO, NF
    MALINCHOC, M
    CHAPMAN, RW
    KAPLAN, MM
    MADDREY, WC
    WILLIAMS, R
    FARRANT, M
    LANGWORTHY, A
    [J]. GASTROENTEROLOGY, 1992, 103 (06) : 1893 - 1901
  • [9] DUAL ASSOCIATION OF HLA DR2 AND DR3 WITH PRIMARY SCLEROSING CHOLANGITIS
    DONALDSON, PT
    FARRANT, JM
    WILKINSON, ML
    HAYLLAR, K
    PORTMANN, BC
    WILLIAMS, R
    [J]. HEPATOLOGY, 1991, 13 (01) : 129 - 133
  • [10] FARRANT MJ, 1992, AMINO ACID SUBSTITUT, V16, P390